Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables - Net: 2020-2022

Historic Receivables - Net for SAB Biotherapeutics (SABS) over the last 3 years, with Dec 2022 value amounting to $5.6 million.

  • SAB Biotherapeutics' Receivables - Net fell 96.21% to $364,117 in Q2 2023 from the same period last year, while for Jun 2023 it was $364,117, marking a year-over-year decrease of 96.21%. This contributed to the annual value of $5.6 million for FY2022, which is 30.64% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Receivables - Net stood at $5.6 million for FY2022, which was down 30.64% from $8.0 million recorded in FY2021.
  • Over the past 5 years, SAB Biotherapeutics' Receivables - Net peaked at $20.6 million during FY2020, and registered a low of $5.6 million during FY2022.
  • Moreover, its 3-year median value for Receivables - Net was $8.0 million (2021), whereas its average is $11.4 million.
  • Data for SAB Biotherapeutics' Receivables - Net shows a maximum YoY tumbled of 61.06% (in 2021) over the last 5 years.
  • Over the past 3 years, SAB Biotherapeutics' Receivables - Net (Yearly) stood at $20.6 million in 2020, then slumped by 61.06% to $8.0 million in 2021, then plummeted by 30.64% to $5.6 million in 2022.